We developed a humanized bifunctional antibody (mPEG×tumor marker),the anti-PEG end can be non-covalently modified to bind any PEGylated nano-druga contrast agent by one-step "formulation". The non-covalent binding solved the problems of chemical modification such as the masking of the antibody binding site, heterogeneity, drug instability. The other end of the bifunctional antibody can specifical

1."One-step formulation" non-covalent bond modification combined with any PEGylated nanomolecule
2. Non-covalent bond modification solved the problems caused by chemical modification, such as masking antibody epitope, heterogeneity,drug instability after modification.
3. Specific target cancer metastasis cancer for treatment
4. Can be replaced with different cancer targetsdrug accumulation for all

1. The convenience use of clinical modification method by "one step formulation"
2. Can be applied to all PEGylated nano-drugscontrast agents
3. Diversity of tumor targets (personalized medicine)
4. "Humanized" bifunctional antibodies meet FDA standardscould accelerate the clinical trial processesreduce the research costs.